Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of beta-amino di-Carbonyl Derivatives


Ben Hadda T., Rauf A., Zgou H., ŞENOL DENİZ F. S., ERDOĞAN ORHAN İ., Mabkhot Y. N., ...More

MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol.19, no.8, pp.688-705, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 19 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.2174/1389557518666181102102816
  • Journal Name: MINI-REVIEWS IN MEDICINAL CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.688-705
  • Keywords: beta-Amino dicarbonyl, cholinesterase inhibition, Alzheimer's disease (AD), DFT calculations, Petra/Osiris/Molinspiration (POM) analysis, in vitro, EXPERIMENTAL-VERIFICATION, ANTIOXIDANT ACTIVITIES, SCHIFF-BASES, ANTIBACTERIAL, IDENTIFICATION, BIOACTIVITY, COMPLEXES
  • Lokman Hekim University Affiliated: No

Abstract

Background: Since deficit of acetylcholine has been evidenced in the Alzheimer's disease (AD) patients, cholinesterase inhibitors are currently the most specified drug category for the remediation of AD.